Fig. 1.

Average tumor multiplicity of mice at 45 weeks after the initiation of DOX treatment. The average tumor multiplicity for each treatment group is expressed as number of tumors per mouse/total number of mice with tumors ±SE. DOX only treated group (D), DOX/BHT co-treated group (DB), DOX/BHT/sulindac co-treated group (DBS), DOX/sulindac co-treated group (DS), DOX/BHT/curcumin co-treated group (DBC) and DOX/curcumin co-treated group (DC). *Denotes statistical significance from DOX-treated group, where P-value is <0.05.